AI Engines For more Details: Perplexity Kagi Labs You
Antiplatelet Effects: Ozagrel hydrochloride works by inhibiting the enzyme thromboxane A2 synthase, thereby reducing the production of thromboxane A2, a potent platelet aggregator. By inhibiting platelet aggregation, ozagrel helps prevent the formation of blood clots (thrombi) and reduces the risk of thrombotic events, such as myocardial infarction, stroke, and peripheral arterial disease.
Cardiovascular Protection: Ozagrel hydrochloride is used in the management of various cardiovascular conditions, including acute coronary syndrome, unstable angina, myocardial infarction, and coronary artery disease. It helps improve blood flow to the heart and reduce the risk of ischemic events by inhibiting platelet activation and thrombus formation.
Cerebrovascular Protection: Ozagrel hydrochloride is also used in the prevention and treatment of cerebrovascular diseases, such as ischemic stroke and transient ischemic attacks (TIAs or "mini-strokes"). By inhibiting platelet aggregation and reducing thrombus formation, ozagrel helps prevent the occlusion of blood vessels in the brain, thereby reducing the risk of stroke recurrence.
Peripheral Vascular Disease: Ozagrel hydrochloride may be used in the management of peripheral arterial disease (PAD), a condition characterized by narrowing or blockage of blood vessels in the legs, arms, or other peripheral areas. By improving blood flow and reducing platelet aggregation, ozagrel can alleviate symptoms such as leg pain (claudication) and promote tissue perfusion.
Anti-inflammatory Effects: In addition to its antiplatelet properties, ozagrel hydrochloride exhibits anti-inflammatory effects by inhibiting the production of inflammatory mediators, such as prostaglandins and leukotrienes. This anti-inflammatory action may contribute to its therapeutic effects in certain conditions associated with inflammation, such as rheumatoid arthritis and inflammatory bowel disease.
Gastrointestinal Protection: Ozagrel hydrochloride may help protect the gastrointestinal mucosa and reduce the risk of gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs) or other antiplatelet medications. Its antiplatelet and anti-inflammatory effects contribute to the maintenance of gastrointestinal integrity.
Side Effects: Common side effects of ozagrel hydrochloride may include gastrointestinal disturbances (such as nausea, vomiting, and abdominal discomfort), headache, dizziness, and rash. Serious side effects, including allergic reactions and bleeding complications, are rare but possible and require medical attention if experienced.
Drug Interactions: Ozagrel hydrochloride may interact with other medications, particularly anticoagulants, antiplatelet agents, and nonsteroidal anti-inflammatory drugs (NSAIDs), increasing the risk of bleeding. It's essential to inform healthcare providers about all medications, supplements, and herbal products being taken to avoid potential interactions.
Pregnancy and Breastfeeding: The safety of ozagrel hydrochloride during pregnancy and breastfeeding has not been well-established. It should be used with caution in pregnant or breastfeeding women, and the potential risks and benefits should be carefully considered before administration.
Liver and Kidney Function: Ozagrel hydrochloride should be used with caution in patients with impaired liver or kidney function, as dosage adjustments may be necessary based on the severity of impairment. Close monitoring of liver and kidney function may be required during treatment.
Dosage and Administration: Ozagrel hydrochloride is typically administered orally in the form of tablets or capsules. The dosage and frequency of administration vary depending on the indication, patient factors, and treatment response. It should be taken as directed by a healthcare professional.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0 | 0 | |
| ADHD | 0.7 | 0.7 | 0 |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | 0 | 0 |
| Allergic Rhinitis (Hay Fever) | 0.2 | 0.2 | |
| Allergies | 0.6 | 0.5 | 0.2 |
| Allergy to milk products | 0.4 | 0 | 0 |
| Alzheimer's disease | 0.6 | 2.1 | -2.5 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.7 | 0.2 | 2.5 |
| Ankylosing spondylitis | 0.3 | -0.3 | |
| Anorexia Nervosa | 0 | 0.7 | 0 |
| Antiphospholipid syndrome (APS) | 0 | 0 | |
| Asthma | 0.7 | 0.2 | 2.5 |
| Atherosclerosis | 0.2 | 0.2 | 0 |
| Atrial fibrillation | 0.9 | 0.2 | 3.5 |
| Autism | 2.2 | 2 | 0.1 |
| Bipolar Disorder | 0.4 | 1 | -1.5 |
| Brain Trauma | 0.2 | -0.2 | |
| Carcinoma | 0.7 | 0.3 | 1.33 |
| Celiac Disease | 0.4 | 0.4 | 0 |
| Cerebral Palsy | 0.1 | 0.4 | -3 |
| Chronic Fatigue Syndrome | 1.7 | 1.6 | 0.06 |
| Chronic Kidney Disease | 0.4 | 0.9 | -1.25 |
| Chronic Lyme | 0.2 | -0.2 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.5 | -0.5 | |
| Chronic Urticaria (Hives) | 0.1 | 0.3 | -2 |
| Coagulation / Micro clot triggering bacteria | 0 | 0.3 | 0 |
| Colorectal Cancer | 0.7 | 0.2 | 2.5 |
| Constipation | 0.4 | 0.1 | 3 |
| Coronary artery disease | 0.4 | 0.4 | 0 |
| COVID-19 | 1.5 | 2.7 | -0.8 |
| Crohn's Disease | 1.7 | 1.5 | 0.13 |
| cystic fibrosis | 0.2 | -0.2 | |
| deep vein thrombosis | 0.3 | -0.3 | |
| Depression | 2.2 | 2.4 | -0.09 |
| Eczema | 0.4 | -0.4 | |
| Endometriosis | 0.5 | 0.2 | 1.5 |
| Epilepsy | 0.4 | 0.2 | 1 |
| Fibromyalgia | 0.3 | 1.1 | -2.67 |
| Functional constipation / chronic idiopathic constipation | 1 | 1.1 | -0.1 |
| gallstone disease (gsd) | 0.3 | 0.1 | 2 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.6 | |
| Generalized anxiety disorder | 0.6 | -0.6 | |
| giant cell arteritis | 0.1 | -0.1 | |
| Gout | 0.4 | -0.4 | |
| Graves' disease | 0.1 | 0.1 | 0 |
| Halitosis | 0.1 | 0.1 | |
| Hashimoto's thyroiditis | 0.2 | 0.1 | 1 |
| Hidradenitis Suppurativa | 0 | 0 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.6 | 0.2 | 2 |
| hypercholesterolemia (High Cholesterol) | 0.1 | 0.1 | |
| hyperglycemia | 0.1 | -0.1 | |
| hypersomnia | 0 | 0 | |
| hypertension (High Blood Pressure | 0.3 | 1.1 | -2.67 |
| Hypothyroidism | 0.7 | -0.7 | |
| Hypoxia | 0.1 | 0.1 | |
| IgA nephropathy (IgAN) | 0.2 | -0.2 | |
| Inflammatory Bowel Disease | 0.7 | 2.2 | -2.14 |
| Insomnia | 0.1 | 0.2 | -1 |
| Intelligence | 0.6 | 0.6 | |
| Intracranial aneurysms | 0.3 | 0.3 | |
| Irritable Bowel Syndrome | 0.6 | 0.7 | -0.17 |
| Liver Cirrhosis | 1 | 0.9 | 0.11 |
| Long COVID | 2 | 1.4 | 0.43 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.1 | 0.2 | -1 |
| ME/CFS with IBS | 0.2 | 0.9 | -3.5 |
| ME/CFS without IBS | 1.1 | 0.1 | 10 |
| Metabolic Syndrome | 1.7 | 1.9 | -0.12 |
| Mood Disorders | 3.1 | 2.7 | 0.15 |
| Multiple Sclerosis | 1.2 | 1.5 | -0.25 |
| Multiple system atrophy (MSA) | 0.2 | 0.2 | 0 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.1 | 1.1 | -10 |
| Obesity | 1.3 | 0.7 | 0.86 |
| obsessive-compulsive disorder | 1.2 | 0.7 | 0.71 |
| Osteoarthritis | 0.2 | 0.2 | 0 |
| Osteoporosis | 0.7 | 0.1 | 6 |
| Parkinson's Disease | 0.8 | 1.2 | -0.5 |
| Polycystic ovary syndrome | 0.7 | 0.6 | 0.17 |
| Postural orthostatic tachycardia syndrome | 0.1 | 0.4 | -3 |
| Premenstrual dysphoric disorder | 0 | 0 | |
| primary biliary cholangitis | 0.1 | -0.1 | |
| Psoriasis | 0.6 | 0.6 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.1 | 1 | 0.1 |
| Rosacea | 0.2 | 0.2 | 0 |
| Schizophrenia | 1.5 | 0.8 | 0.88 |
| scoliosis | 0.4 | 0.2 | 1 |
| Sjögren syndrome | 0 | 0.5 | 0 |
| Sleep Apnea | 0.6 | 0.9 | -0.5 |
| Stress / posttraumatic stress disorder | 0.3 | 1.2 | -3 |
| Systemic Lupus Erythematosus | 1.1 | 0.3 | 2.67 |
| Tic Disorder | 0.5 | 0.5 | |
| Tourette syndrome | 0.1 | -0.1 | |
| Type 1 Diabetes | 1.3 | 0.5 | 1.6 |
| Type 2 Diabetes | 1.9 | 1.6 | 0.19 |
| Ulcerative colitis | 0.2 | 1.2 | -5 |
| Unhealthy Ageing | 1.6 | 0.9 | 0.78 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.